close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genprex, Inc. - Common Stock (NQ:GNPX)

1.860 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Data Supporting Therapeutic Potential of Its Non-Viral Delivery System
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Research Findings, Additional Support for REQORSA(R) and Its Therapeutic Potential
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Statement Regarding FDA Initiative to Accelerate Approval Process for Gene Therapies
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Barcelona Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $4M Registered Direct Offering
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Inks Deal with University of Pittsburgh for Exclusive License to Diabetes Technology
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Gene Therapy Treatment Data to be Presented at Upcoming International Diabetes Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial, Licenses Additional Technology from University of Pittsburgh
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Gene Therapies for Cancer and Diabetes at Upcoming Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Upcoming Investor, Industry Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial to Higher Dose
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in June Investor Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment
Via Investor Brand Network
News headline image
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference
Via Investor Brand Network
News headline image
Genprex to Participate in Upcoming Investor Conference in March
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences
Via Investor Brand Network
News headline image
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System
Via Investor Brand Network
News headline image
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today